Literature DB >> 29872472

The Story of NAIMIT - A Framework 7 Project on Type 1 Diabetes.

Chantal Mathieu1, Lut Overbergh2.   

Abstract

NAIMIT (acronym for Natural Immune Modulation for Intervention in Type 1 Diabetes) is a large-scale collaborative programme of the 7th framework from the European Commission. The aim of the consortium is to bring together a group of leading European researchers spanning the field from genetics, through pancreatic beta-cell, dendritic cells and T-cell biology, towards clinical interventions. The ultimate goal is to develop novel and personalised interventional therapies in recent-onset type 1 diabetic patients, with minimal immune system interference, leading to beta-cell protection and restoration, based on a solid understanding of the disease pathogenesis, enabling experimental findings to be adopted for clinical applications.

Entities:  

Keywords:  Type 1 diabetes; intervention; personalised therapies

Year:  2014        PMID: 29872472      PMCID: PMC5983077          DOI: 10.17925/EE.2014.10.02.100

Source DB:  PubMed          Journal:  Eur Endocrinol        ISSN: 1758-3772


  16 in total

1.  IL-17A increases the expression of proinflammatory chemokines in human pancreatic islets.

Authors:  Fabio A Grieco; Fabrice Moore; François Vigneron; Izortze Santin; Olatz Villate; Lorella Marselli; Dieter Rondas; Hannelie Korf; Lutgart Overbergh; Francesco Dotta; Piero Marchetti; Chantal Mathieu; Décio L Eizirik
Journal:  Diabetologia       Date:  2013-12-19       Impact factor: 10.122

2.  Differential protein pathways in 1,25-dihydroxyvitamin d(3) and dexamethasone modulated tolerogenic human dendritic cells.

Authors:  Gabriela Bomfim Ferreira; Fleur S Kleijwegt; Etienne Waelkens; Kasper Lage; Tatjana Nikolic; Daniel Aaen Hansen; Christopher T Workman; Bart O Roep; Lut Overbergh; Chantal Mathieu
Journal:  J Proteome Res       Date:  2011-12-15       Impact factor: 4.466

3.  Oral delivery of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice.

Authors:  Sofie Robert; Conny Gysemans; Tatiana Takiishi; Hannelie Korf; Isabella Spagnuolo; Guido Sebastiani; Karolien Van Huynegem; Lothar Steidler; Silvia Caluwaerts; Pieter Demetter; Clive H Wasserfall; Mark A Atkinson; Francesco Dotta; Pieter Rottiers; Tom L Van Belle; Chantal Mathieu
Journal:  Diabetes       Date:  2014-03-27       Impact factor: 9.461

4.  Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study.

Authors:  S L Thrower; L James; W Hall; K M Green; S Arif; J S Allen; C Van-Krinks; B Lozanoska-Ochser; L Marquesini; S Brown; F S Wong; C M Dayan; M Peakman
Journal:  Clin Exp Immunol       Date:  2008-11-20       Impact factor: 4.330

5.  Discovery of molecular pathways mediating 1,25-dihydroxyvitamin D3 protection against cytokine-induced inflammation and damage of human and male mouse islets of Langerhans.

Authors:  H Wolden-Kirk; D Rondas; M Bugliani; H Korf; L Van Lommel; K Brusgaard; H T Christesen; F Schuit; P Proost; M Masini; P Marchetti; D L Eizirik; L Overbergh; C Mathieu
Journal:  Endocrinology       Date:  2014-01-01       Impact factor: 4.736

6.  1,25-Dihydroxyvitamin D3 promotes tolerogenic dendritic cells with functional migratory properties in NOD mice.

Authors:  Gabriela B Ferreira; Conny A Gysemans; Jocelyne Demengeot; João Paulo M C M da Cunha; An-Sofie Vanherwegen; Lut Overbergh; Tom L Van Belle; Femke Pauwels; Annemieke Verstuyf; Hannelie Korf; Chantal Mathieu
Journal:  J Immunol       Date:  2014-03-24       Impact factor: 5.422

7.  Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated β-cell death.

Authors:  Sefina Arif; Fabrice Moore; Katherine Marks; Thomas Bouckenooghe; Colin M Dayan; Raquel Planas; Marta Vives-Pi; Jake Powrie; Timothy Tree; Piero Marchetti; Guo Cai Huang; Esteban N Gurzov; Ricardo Pujol-Borrell; Decio L Eizirik; Mark Peakman
Journal:  Diabetes       Date:  2011-06-09       Impact factor: 9.461

8.  GLIS3, a susceptibility gene for type 1 and type 2 diabetes, modulates pancreatic beta cell apoptosis via regulation of a splice variant of the BH3-only protein Bim.

Authors:  Tatiane C Nogueira; Flavia M Paula; Olatz Villate; Maikel L Colli; Rodrigo F Moura; Daniel A Cunha; Lorella Marselli; Piero Marchetti; Miriam Cnop; Cécile Julier; Decio L Eizirik
Journal:  PLoS Genet       Date:  2013-05-30       Impact factor: 5.917

9.  Regulatory multitasking of tolerogenic dendritic cells - lessons taken from vitamin d3-treated tolerogenic dendritic cells.

Authors:  Tatjana Nikolic; Bart O Roep
Journal:  Front Immunol       Date:  2013-05-14       Impact factor: 7.561

10.  Can we vaccinate against Type 1 diabetes?

Authors:  Mark Peakman
Journal:  F1000 Biol Rep       Date:  2012-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.